Lernik Ohanjanian

A systematic review and meta-analysis of preclinical trials testing anti-toxin therapies for B. anthracis infection: A need for more robust study designs and results

X. Cui, P. Eichacker, Wanying Xu, 2017, PloS one.

Does Bacillus anthracis Lethal Toxin Directly Depress Myocardial Function? A Review of Clinical Cases and Preclinical Studies

X. Cui, P. Eichacker, Yan Li, 2015, Toxins.

Nitric oxide production contributes to Bacillus anthracis edema toxin-associated arterial hypotension and lethality: ex vivo and in vivo studies in the rat.

S. Leppla, M. Moayeri, X. Cui, 2016, American journal of physiology. Heart and circulatory physiology.

Bacillus anthracis edema but not lethal toxin challenge in rats is associated with depressed myocardial function in hearts isolated and tested in a Langendorff system.

X. Cui, P. Eichacker, Y. Fitz, 2015, American journal of physiology. Heart and circulatory physiology.

Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

I. Flinn, H. Deeg, F. Thol, 2021, Leukemia.

An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis

X. Cui, P. Eichacker, Yan Li, 2015, Expert opinion on investigational drugs.

Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers

P. Meltzer, M. Wei, C. Ricketts, 2018, Oncotarget.

Bacillus anthracis Edema Toxin Increases Fractional Free Water and Sodium Reabsorption in an Isolated Perfused Rat Kidney Model

P. Torabi-Parizi, X. Cui, P. Eichacker, 2017, Infection and Immunity.

377 AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects

D. Underwood, A. Tolcher, M. Findeis, 2020 .